EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Adipose Tissue‐Targeted Delivery of Rosiglitazone With Iron Oxide Nanoparticles Ameliorates Insulin Resistance in Male Mice

Jakob E Ostberg, Zeeshan Ahmed, Katayoun Saatchi, Parleen K Pandher iD, Yamna Rahim, Urs O Häfeli iD, Sarah L Gray iD

Obesity · 2026-05 · 34 (5) · 1068-1080

DOI: 10.1002/oby.70182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity, online erschienen am 31.03.2026. Verfasst von Jakob E Ostberg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Sciences, University of Northern British Columbia, Prince George, British Columbia, Canada. Hauptthemen laut MEDLINE: Rosiglitazone, Insulin Resistance, Magnetic Iron Oxide Nanoparticles, Obesity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: New Frontiers in Research Fund - Expoloration, Tier 2 Canada Research Chair - Integrative Physiology of Diabetes, CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to assess iron oxide magnetic nanoparticles (MNPs) for adipose tissue‐targeted therapeutics to restore adipose tissue function and insulin sensitivity in obesity.

Methods

The insulin‐sensitizing effects of rosiglitazone and known adverse effects were leveraged for this proof‐of‐concept assessment of adipose tissue drug targeting. Rosiglitazone was adsorbed to alendronic acid‐coated MNPs (rosiMNPs) and a biocompatible magnet implanted in the right inguinal white adipose tissue (ingWAT) of obese, insulin resistant male mice. Following rosiMNP treatment (1.5 mg/kg/day, 18 days), insulin sensitivity and adipose tissue health were assessed.

Results

RosiMNPs restored insulin sensitivity as well as systemic rosiglitazone (1.5 mg/kg/day, 18 days), with a shift in adipocyte size compatible with PPARγ‐induced adipocyte hyperplasia and no increase in circulating adiponectin. PPARγ target genes were induced in ingWAT with rosiMNPs or systemic rosiglitazone, but only in liver and gonadal WAT of systemically treated mice. Additionally, iron accumulation was shown in the right, targeted ingWAT depot, but not in the left, untargeted ingWAT, kidney, or liver, suggesting targeting was achieved. Unfortunately, the dose and duration of systemic treatment were ineffective at inducing changes in kidney.

Conclusions

Results demonstrate the potential benefits of adipose tissue‐targeted therapeutics to improve adipose tissue function to restore insulin sensitivity to prevent the metabolic complications of obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RosiglitazoneInsulin ResistanceMagnetic Iron Oxide NanoparticlesObesityAdipose Tissue, WhiteHypoglycemic AgentsThiazolidinedionesAdipose TissueAnimalsMaleMicePPAR-gamma AgonistsPPAR gammaAdipocytesMice, Inbred C57BLAdiponectinDrug Delivery Systems

Stichwörter der Autor:innen

PPAR gammaadipose tissueinsulin resistancenanotechnologyobesity

Substanzen

RosiglitazonePPAR-gamma AgonistsPPAR gammaHypoglycemic AgentsAdiponectinThiazolidinediones

Autor:innen und Institutionen

  • Division of Medical Sciences, University of Northern British Columbia, Prince George, British Columbia, Canada.
  • Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

ORCID-Profile: Parleen K Pandher, Urs O Häfeli, Sarah L Gray

Förderung

  • New Frontiers in Research Fund - Expoloration
  • Tier 2 Canada Research Chair - Integrative Physiology of Diabetes
  • CIHR
  • Natural Sciences and Engineering Research Council of Canada
  • University of Northern British Columbia
  • Canadian Institutes of Health Research

Zitieren

APA

Ostberg, J. E., Ahmed, Z., Saatchi, K., Pandher, P. K., Rahim, Y., Häfeli, U. O., & Gray, S. L. (2026). Adipose Tissue‐Targeted Delivery of Rosiglitazone With Iron Oxide Nanoparticles Ameliorates Insulin Resistance in Male Mice. Obesity, 34(5), 1068-1080. https://doi.org/10.1002/oby.70182

Vancouver

Ostberg JE, Ahmed Z, Saatchi K, Pandher PK, Rahim Y, Häfeli UO, et al. Adipose Tissue‐Targeted Delivery of Rosiglitazone With Iron Oxide Nanoparticles Ameliorates Insulin Resistance in Male Mice. Obesity. 2026;34(5):1068-1080. doi:10.1002/oby.70182

BibTeX
@article{Ostberg2026,
  author = {Ostberg, Jakob E and Ahmed, Zeeshan and Saatchi, Katayoun and Pandher, Parleen K and Rahim, Yamna and Häfeli, Urs O and Gray, Sarah L},
  title = {Adipose Tissue‐Targeted Delivery of Rosiglitazone With Iron Oxide Nanoparticles Ameliorates Insulin Resistance in Male Mice},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {5},
  pages = {1068--1080},
  doi = {10.1002/oby.70182}
}
Kostenlos starten →